Table 1 Demographic characteristics of HC and TRD populations

From: Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome

 

HC

TRD

P-value

Paricipants, n (%)

26 (44%)

33 (56%)

 

Gender (M/F)

14/14

21/14

0.303

Age at enrollment

39.0±11.1

44.8±13.6

0.082

Body mass index

27.2±5.3

28.2±6.2

0.189

Race, n (%)

  

0.062

 Caucasian

12 (46%)

25 (76%)

 

 African-American

8 (31%)

4 (12%)

 

 Other

6 (23%)

4 (12%)

 

Ethnicity

  

0.390

 Hispanic

4 (14%)

2 (6%)

 

 Non-Hispanic

22 (85%)

31 (94%)

 

Depression history

 # Lifetime MDE

—

4.71±7.3

 

 # Failed AD trials

—

5.21±2.7

 

 Failed SSRI, n (%)

—

28 (80%)

 

 Failed SNRI, n (%)

—

23 (66%)

 

 Failed atypical AD, n (%)

—

21 (60%)

 

 Failed MAOI, n (%)

—

8 (23%)

 

 Failed tricyclic, n (%)

—

7 (20%)

 

 Failed ECT, n (%)

—

5 (14%)

 

 Hx of augmentation trial, n (%)

—

18 (51%)

 

 Hx of suicide attempt

—

8 (23%)

 

 Past SUD, n (%)

—

2 (6%)

 

 Hx anxiety disorder, n (%)

—

7 (20%)

 

 Baseline MADRS score

—

33.0±4.4

 

 Baseline QIDS-SR score

3.5±3.5

17.9±4.4

<0.0001

  1. Abbreviations: AD, antidepressant; ECT, electroconvulsive therapy; HC, healthy control; MADRS, Montgomery–Åsberg Depression Rating Scale; MAOI, monoamine oxidase inhibitor; MDE, major depressive episode; QIDS-SR, Quick Inventory of Depressive Symptomatology - Self Report; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; SUD, substance use disorder; TRD, treatment-resistant depression.
  2. Anxiety disorder is defined as diagnosis of generalized anxiety disorder or panic disorder. Differences in categorical variables were analyzed with χ2 analysis, and continuous variables compared with t-test.
Back to article page